Rahul A. Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rahul A. Sharma has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Thanansayan Dhivagaran
Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 5C1, Canada
4 shared publications Arun Sundaram
3 shared publicationsAswen Sriranganathan
Faculty of Medicine, University of Ottawa, Ottawa, ON
3 shared publications- Brendan K. Tao
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada
3 shared publications - Angelica Hanna
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2 shared publications Arnav Gupta
2 shared publications
Latest Publications
- 22 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (12)
Risk of Idiopathic Intracranial Hypertension Following Anemia in Young Adults
- 22 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (12)
Risk of Idiopathic Intracranial Hypertension Following Anemia in Young Adults
- 4 June 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1168-1173
Geospatial access to neuro-ophthalmologists in Canada: a regional analysis
- 4 June 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1168-1173
Geospatial access to neuro-ophthalmologists in Canada: a regional analysis
- 18 May 2026
Obstructive sleep apnea and idiopathic intracranial hypertension: a systematic review and meta-analysis.
To determine the pooled prevalence of obstructive sleep apnea (OSA) among adults with idiopathic intracranial hypertension (IIH) using polysomnography (PSG) and the Berlin Questionnaire screening. IIH is a vision-threatening disorder characterized by elevated intracranial pressure. OSA shares overlapping risk factors and pathophysiological mechanisms with IIH, including nocturnal hypoxia and hypercapnia. Clarifying OSA prevalence in IIH is clinically important for diagnosis and management. For this prospectively registered systematic review and meta-analysis (PROSPERO: CRD420251132794), we searched MEDLINE, Embase, and CENTRAL from inception to August 23, 2025, for studies reporting PSG-confirmed OSA or Berlin Questionnaire positivity in adults with IIH. Risk of bias was assessed using ROBINS-I and RoB-2, and certainty of evidence was checked using the Grading of Recommendations, Assessment, Development and Evaluation tool. Random-effects meta-analyses of proportions generated pooled prevalence estimates. Subgroup analyses excluded high-risk studies, leave-one-out analyses assessed robustness, and funnel plots evaluated publication bias. Eleven studies met the inclusion criteria. Across 9 PSG-based studies (n = 299), the pooled prevalence of OSA in IIH was 0.44 (95% CI: 0.26-0.63; I² = 90.5%). Leave-one-out analyses showed stable results (39%-50%). Excluding high-risk studies (4 studies; n = 132) yielded a pooled prevalence of 0.53 (95% CI: 0.32-0.74). Four Berlin Questionnaire studies (n = 154) showed a pooled prevalence of 0.65 (95% CI: 0.54-0.74; I² = 0%). Funnel plot asymmetry suggested publication bias, and certainty of evidence was very low. OSA is common among patients with IIH, supporting routine objective sleep evaluation. Prospective studies are needed to clarify this association.
- 18 May 2026
Obstructive sleep apnea and idiopathic intracranial hypertension: a systematic review and meta-analysis.
To determine the pooled prevalence of obstructive sleep apnea (OSA) among adults with idiopathic intracranial hypertension (IIH) using polysomnography (PSG) and the Berlin Questionnaire screening. IIH is a vision-threatening disorder characterized by elevated intracranial pressure. OSA shares overlapping risk factors and pathophysiological mechanisms with IIH, including nocturnal hypoxia and hypercapnia. Clarifying OSA prevalence in IIH is clinically important for diagnosis and management. For this prospectively registered systematic review and meta-analysis (PROSPERO: CRD420251132794), we searched MEDLINE, Embase, and CENTRAL from inception to August 23, 2025, for studies reporting PSG-confirmed OSA or Berlin Questionnaire positivity in adults with IIH. Risk of bias was assessed using ROBINS-I and RoB-2, and certainty of evidence was checked using the Grading of Recommendations, Assessment, Development and Evaluation tool. Random-effects meta-analyses of proportions generated pooled prevalence estimates. Subgroup analyses excluded high-risk studies, leave-one-out analyses assessed robustness, and funnel plots evaluated publication bias. Eleven studies met the inclusion criteria. Across 9 PSG-based studies (n = 299), the pooled prevalence of OSA in IIH was 0.44 (95% CI: 0.26-0.63; I² = 90.5%). Leave-one-out analyses showed stable results (39%-50%). Excluding high-risk studies (4 studies; n = 132) yielded a pooled prevalence of 0.53 (95% CI: 0.32-0.74). Four Berlin Questionnaire studies (n = 154) showed a pooled prevalence of 0.65 (95% CI: 0.54-0.74; I² = 0%). Funnel plot asymmetry suggested publication bias, and certainty of evidence was very low. OSA is common among patients with IIH, supporting routine objective sleep evaluation. Prospective studies are needed to clarify this association.
- 16 May 2026
Geospatial access to neuro-ophthalmologists in Canada: a regional analysis.
There is an undersupply of neuro-ophthalmologists in North America compared to care demand, which may be further compounded by barriers to care access, such as geography, education, and socioeconomic status. In this study, we sought to analyze the national distribution of neuro-ophthalmologists in Canada and evaluate factors associated with impeded care access. A list of all neuro-ophthalmologists in Canada was compiled using the North American Neuro-Ophthalmology Society directory, Canadian Neuro-ophthalmology Group directory, and additional input from the authors. Canadian Census data from 2021 was collected at the level of aggregated dissemination areas (ADAs). The 3-step floating catchment area (3SFCA) method was used to assess accessibility to neuro-ophthalmologists across ADAs. Logistic regression models were created using the accessibility score to determine factors that impact accessibility. Of the 5 433 ADAs in Canada, 1 817 (33%) are located further than 100 km from the nearest neuro-ophthalmologist. The mean distance to a neuro-ophthalmologist was 155.0 km, while the median was 33.0 km. The overall 3SFCA-adjusted rate of accessibility in Canada was 0.015 neuro-ophthalmologists per 100,000 people. Regression analysis found rural residency (odds ratio [OR] = 0.56; p < 0.001) to be the most significant factor associated with reduced access to neuro-ophthalmological care, while areas with higher Indigenous population percentages were associated with reduced access to care (OR = 0.36; p < 0.001). There are disparities in access to neuro-ophthalmologists across Canada. Rural residence and an increased Indigenous population were found to be significant factors associated with reduced access to neuro-ophthalmological care. Further research should investigate strategies to mitigate these discrepancies.
- 16 May 2026
Geospatial access to neuro-ophthalmologists in Canada: a regional analysis.
There is an undersupply of neuro-ophthalmologists in North America compared to care demand, which may be further compounded by barriers to care access, such as geography, education, and socioeconomic status. In this study, we sought to analyze the national distribution of neuro-ophthalmologists in Canada and evaluate factors associated with impeded care access. A list of all neuro-ophthalmologists in Canada was compiled using the North American Neuro-Ophthalmology Society directory, Canadian Neuro-ophthalmology Group directory, and additional input from the authors. Canadian Census data from 2021 was collected at the level of aggregated dissemination areas (ADAs). The 3-step floating catchment area (3SFCA) method was used to assess accessibility to neuro-ophthalmologists across ADAs. Logistic regression models were created using the accessibility score to determine factors that impact accessibility. Of the 5 433 ADAs in Canada, 1 817 (33%) are located further than 100 km from the nearest neuro-ophthalmologist. The mean distance to a neuro-ophthalmologist was 155.0 km, while the median was 33.0 km. The overall 3SFCA-adjusted rate of accessibility in Canada was 0.015 neuro-ophthalmologists per 100,000 people. Regression analysis found rural residency (odds ratio [OR] = 0.56; p < 0.001) to be the most significant factor associated with reduced access to neuro-ophthalmological care, while areas with higher Indigenous population percentages were associated with reduced access to care (OR = 0.36; p < 0.001). There are disparities in access to neuro-ophthalmologists across Canada. Rural residence and an increased Indigenous population were found to be significant factors associated with reduced access to neuro-ophthalmological care. Further research should investigate strategies to mitigate these discrepancies.
- 16 April 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (4) , 908-917
Risk factors for ethambutol-induced optic neuropathy: a systematic review and meta-analysis of comparative studies
- 16 April 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (4) , 908-917
Risk factors for ethambutol-induced optic neuropathy: a systematic review and meta-analysis of comparative studies
- Open Access
- 1 April 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (5) , 108629
Sociodemographic disparities in self-reported stroke: A cross-sectional, population-based analysis
- 1 April 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (5) , 108629
Open AccessSociodemographic disparities in self-reported stroke: A cross-sectional, population-based analysis
- 26 March 2026
Risk factors for ethambutol-induced optic neuropathy: a systematic review and meta-analysis of comparative studies.
To identify risk factors for ethambutol-induced optic neuropathy (EON). Systematic review and meta-analysis. A literature search was conducted of PubMed, MEDLINE, EMBASE, and grey literature on February 5, 2024. Observational studies describing adults receiving ethambutol with optic neuropathy were included. Extracted data included patient demographics and comorbidities, dose, and duration of treatment with ethambutol, and the number of patients diagnosed with EON. A random-effects meta-analysis was performed for patients with hypertension, and patients with diabetes mellitus. Risk of bias was assessed using the Cochrane's RoB 2.0 tool and ROBINS-I tool. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation. Eleven studies encompassing 370 patients diagnosed with EON were included. Longer duration of ethambutol therapy and the presence of comorbid renal disease were the most consistently associated risk factors. While non-weight-adjusted dosing did not significantly correlate with EON, patients receiving weight-adjusted doses had significantly higher daily dosages among EON cases. hypertension (odds ratio [OR] = 1.86; 95% CI 0.44-7.75; p = 0.11; k = 2) and diabetes mellitus (OR = 0.85; 95% CI 0.54-1.35; p = 0.27; k = 3), although neither reached statistical significance. The certainty of the evidence was low to very low, with wide confidence intervals and imprecise effects. EON is most strongly associated with longer ethambutol duration and renal impairment. The contribution of dosage, hypertension, and diabetes requires further investigation. Overall, judicious planning is required to monitor EON as a potential adverse event of antitubercular therapy.
- 26 March 2026
Risk factors for ethambutol-induced optic neuropathy: a systematic review and meta-analysis of comparative studies.
To identify risk factors for ethambutol-induced optic neuropathy (EON). Systematic review and meta-analysis. A literature search was conducted of PubMed, MEDLINE, EMBASE, and grey literature on February 5, 2024. Observational studies describing adults receiving ethambutol with optic neuropathy were included. Extracted data included patient demographics and comorbidities, dose, and duration of treatment with ethambutol, and the number of patients diagnosed with EON. A random-effects meta-analysis was performed for patients with hypertension, and patients with diabetes mellitus. Risk of bias was assessed using the Cochrane's RoB 2.0 tool and ROBINS-I tool. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation. Eleven studies encompassing 370 patients diagnosed with EON were included. Longer duration of ethambutol therapy and the presence of comorbid renal disease were the most consistently associated risk factors. While non-weight-adjusted dosing did not significantly correlate with EON, patients receiving weight-adjusted doses had significantly higher daily dosages among EON cases. hypertension (odds ratio [OR] = 1.86; 95% CI 0.44-7.75; p = 0.11; k = 2) and diabetes mellitus (OR = 0.85; 95% CI 0.54-1.35; p = 0.27; k = 3), although neither reached statistical significance. The certainty of the evidence was low to very low, with wide confidence intervals and imprecise effects. EON is most strongly associated with longer ethambutol duration and renal impairment. The contribution of dosage, hypertension, and diabetes requires further investigation. Overall, judicious planning is required to monitor EON as a potential adverse event of antitubercular therapy.
- Open Access
- 17 March 2026
- Published by Elsevier in Ophthalmology
- Vol. 133 (7) , 921-931
Incidence of Postoperative Diplopia after Cataract Surgery
- 17 March 2026
- Published by Elsevier in Ophthalmology
- Vol. 133 (7) , 921-931
Open AccessIncidence of Postoperative Diplopia after Cataract Surgery
- 22 January 2026
- Published by Springer Nature in Eye
- Vol. 40 (5) , 603-610
Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis
Background/objectives Diplopia is an infrequent manifestation of GCA, but may precede other visual disturbances such as transient or permanent vision loss. The literature-pooled prevalence of diplopia in GCA patients stratified by cranial nerve (CN) involvement was assessed. Methods/literature reviewed The protocol was registered prospectively (PROSPERO: CRD420251071956). MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to April 17, 2025. Studies were included if they reported on the proportion of diplopia events in patients with GCA. Literature screening, data extraction, and risk of bias (ROB) assessments were performed independently and in duplicate. A non-pairwise, random-effects meta-analysis was performed. Results 50 studies were included, encompassing 21,680 patients with GCA and 664 diplopia events. Overall, the pooled prevalence of diplopia in GCA patients was 7.15% (95% CI = 5.52–9.22%). The pooled prevalence of diplopia in GCA patients with CN III involvement was 0.96% (95% CI = 0.35–2.60%). The pooled prevalence of diplopia in GCA patients with CN IV involvement was 0.30% (95% CI = 0.07–1.26%). The pooled prevalence of diplopia in GCA patients with CN VI involvement was 1.41% (95% CI = 0.54–3.62%). Excluding studies with high risk of ROB, the pooled prevalence of diplopia in GCA patients was 7.14% (95% CI = 5.44–9.33%). Conclusion Overall, 7.15% of patients with GCA experience diplopia, more frequently reported due to abducens nerve palsy compared to oculomotor and trochlear nerve palsies. Accordingly, new-onset binocular diplopia in adults may warrant consideration of GCA and further investigation. Future prospective studies should aim to better characterise underlying aetiologies and assess whether early recognition of diplopia translates to improved visual prognosis.
- 22 January 2026
- Published by Springer Nature in Eye
- Vol. 40 (5) , 603-610
Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis
Background/objectives Diplopia is an infrequent manifestation of GCA, but may precede other visual disturbances such as transient or permanent vision loss. The literature-pooled prevalence of diplopia in GCA patients stratified by cranial nerve (CN) involvement was assessed. Methods/literature reviewed The protocol was registered prospectively (PROSPERO: CRD420251071956). MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to April 17, 2025. Studies were included if they reported on the proportion of diplopia events in patients with GCA. Literature screening, data extraction, and risk of bias (ROB) assessments were performed independently and in duplicate. A non-pairwise, random-effects meta-analysis was performed. Results 50 studies were included, encompassing 21,680 patients with GCA and 664 diplopia events. Overall, the pooled prevalence of diplopia in GCA patients was 7.15% (95% CI = 5.52–9.22%). The pooled prevalence of diplopia in GCA patients with CN III involvement was 0.96% (95% CI = 0.35–2.60%). The pooled prevalence of diplopia in GCA patients with CN IV involvement was 0.30% (95% CI = 0.07–1.26%). The pooled prevalence of diplopia in GCA patients with CN VI involvement was 1.41% (95% CI = 0.54–3.62%). Excluding studies with high risk of ROB, the pooled prevalence of diplopia in GCA patients was 7.14% (95% CI = 5.44–9.33%). Conclusion Overall, 7.15% of patients with GCA experience diplopia, more frequently reported due to abducens nerve palsy compared to oculomotor and trochlear nerve palsies. Accordingly, new-onset binocular diplopia in adults may warrant consideration of GCA and further investigation. Future prospective studies should aim to better characterise underlying aetiologies and assess whether early recognition of diplopia translates to improved visual prognosis.
- 26 October 2025
- Published by Springer Nature in Eye
- Vol. 40 (1) , 45-50
Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane
Objectives To explore the evidence on the use of anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of peripapillary choroidal neovascular membrane (pCNVM). Methods Medline, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched between January 2000 and December 2024 for relevant articles that used anti-VEGF therapy to treat pCNVM of any origin. This review followed PRISMA guidelines and was prospectively registered (PROSPERO registration number CRD42024551949). Results Ten studies reporting on 269 eyes were included. The most common treatment strategy was pro re nata (PRN), used in 8 studies. One study used a fixed interval regimen, and another used a loading phase followed by PRN. Across all studies, the average number of anti-VEGF injections was 7 per eye over a mean follow-up duration of 34 months (range: 3–44 months). Eight studies reported improvements in best corrected visual acuity (BCVA) at final follow-up following treatment. The mean logarithm of the minimum angle of resolution (logMAR) change was 0.092, or approximately one line Snellen improvement. Two studies reported on macular thickness, and one reported on choroidal thickness after treatment, all of which noted decreased thickness at final follow-up. No significant complications were reported. Conclusions For patients with pCNVM of various aetiologies, anti-VEGF injections using any treatment strategy, including conservative management with a PRN approach, seem to be a safe and effective therapy associated with improved visual acuity.
- 26 October 2025
- Published by Springer Nature in Eye
- Vol. 40 (1) , 45-50
Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane
Objectives To explore the evidence on the use of anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of peripapillary choroidal neovascular membrane (pCNVM). Methods Medline, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched between January 2000 and December 2024 for relevant articles that used anti-VEGF therapy to treat pCNVM of any origin. This review followed PRISMA guidelines and was prospectively registered (PROSPERO registration number CRD42024551949). Results Ten studies reporting on 269 eyes were included. The most common treatment strategy was pro re nata (PRN), used in 8 studies. One study used a fixed interval regimen, and another used a loading phase followed by PRN. Across all studies, the average number of anti-VEGF injections was 7 per eye over a mean follow-up duration of 34 months (range: 3–44 months). Eight studies reported improvements in best corrected visual acuity (BCVA) at final follow-up following treatment. The mean logarithm of the minimum angle of resolution (logMAR) change was 0.092, or approximately one line Snellen improvement. Two studies reported on macular thickness, and one reported on choroidal thickness after treatment, all of which noted decreased thickness at final follow-up. No significant complications were reported. Conclusions For patients with pCNVM of various aetiologies, anti-VEGF injections using any treatment strategy, including conservative management with a PRN approach, seem to be a safe and effective therapy associated with improved visual acuity.